FDA Approves Leqembi, First Drug To Slow Progression of Alzheimer's Disease

The FDA approved Leqembi, the first drug proven to slow cognitive decline from Alzheimer's disease, to treat mild Alzheimer's disease.
Leqembi delayed worsening of symptoms by about five months over 18 months in clinical trials but is not a cure.
The drug will be covered by most health insurance, including Medicare, but out-of-pocket costs could still reach $5,000 per year.
The drug received a black-box warning for potential side effects like brain swelling and bleeding.
Leqembi provides hope for future treatments to slow or halt Alzheimer's disease, which currently has no cure.